Slayback Pharma LLC

Azurity Pharmaceuticals, a Massachusetts-based firm focused on the 505(b)(2) hybrid new drug application pathway, says it looks forward to bringing its commercial expertise to Slayback Pharma’s pipe

Dr. Reddy's Laboratories ’ US business could see volatility on a quarter-to-quarter basis due to the “fundamental nature” of the generic business model. But the Indian firm underscored the prospects o

Dr. Reddy's Laboratories Ltd. ’s US business could see volatility on a quarter-to-quarter basis due to the “fundamental nature” of the generic business model. But the Indian firm underscored the prosp

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. TiumBio, Hansoh Ink $170m Endometr